COVID-19: QUALE TERAPIA ANTI-TROMBOTICA? UNA REVISIONE DEI TRIAL DELLA ASS.AMERICANA DEI CARDIOLOGI
Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19 JACC State-of-the-Art Review Azita H. Talasaz et al. Endothelial injury and microvascular/macrovascular thrombosis are common pathophysiological features of coronavirus disease-2019 (COVID-19). However, the optimal thromboprophylactic regimens remain unknown across the spectrum of illness severity of COVID-19. A variety of antithrombotic agents, doses, and durations of…

